Study on Using Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for Blood Disorders
Sponsor: Masonic Cancer Center, University of Minnesota
ClinicalTrials ID:NCT05805605
This clinical trial is exploring a new approach to stem cell transplants for patients with blood disorders, using a less intense preparation method and specific medications to prevent complications after the transplant.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is testing a new method for stem cell transplants in patients with blood disorders. It uses a less intense preparation process, including medications like cyclophosphamide, fludarabine, and total body irradiation, followed by a stem cell infusion from a related, unrelated, or partially matched family donor. After the transplant, patients receive medications to prevent complications, including post-transplant cyclophosphamide, sirolimus, and MMF.
Eligibility Criteria
Inclusion Criteria
- Ages 0 to 75 with good overall health scores.
- Must have a suitable donor match for stem cell donation.
- Eligible diseases include certain types of leukemia, lymphoma, and other blood disorders.
- Must be in remission or have specific disease characteristics.
- Adequate organ function, including liver, kidney, heart, and lungs.
- Must not have active infections or uncontrolled health conditions.
- Women of childbearing potential and men with partners of childbearing potential must agree to use birth control during the study.
- Must provide written consent to participate.
Exclusion Criteria
- Pregnant or breastfeeding women.
- Untreated active infections.
- Active cancer in the central nervous system.
- Certain aggressive blood cancers that are not responding to treatment.
- Less than 3 months since a previous intense transplant.
- Evidence of disease progression on scans or biopsies.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.